摘要
目的:观察不同核苷(酸)类似物长期治疗拉米夫定耐药慢性乙肝患者的临床疗效。方法:将某院收治的88例拉米夫定耐药慢性乙肝患者分为治疗1组、治疗2组,给予治疗1组患者恩替卡韦治疗,给予治疗两组患者阿德福韦酯联合拉米夫定治疗,两组患者的治疗周期均为12个月。结果:治疗周期结束后治疗1组患者的ALT复常率、HBV-DNA转阴率、HBeAg转阴率略高于治疗两组患者,但组间差异无统计学意义,P>0.05。治疗1组患者对药物的耐药率高于治疗两组,P<0.05。结论:核苷(酸)类似物恩替卡韦、阿德福韦酯治疗拉米夫定耐药慢性乙肝患者均可获得良好疗效,但恩替卡韦长期使用易产生耐药性。
Objective：To investigate the clinical efficacy of different nucleoside（acid）analogues in the long-term treatment of patients with CHB and lamivudine resistance.Methods：88patients with CHB and lamivudine resistance admitted to a hospital were divided into treatment group 1and treatment group 2.Treatment group 1was given entecavir treatment,treatment group 2was given adefovir dipivoxil combined lamivudine treatment,and the treatment period of two groups were 12 months.Results：After treatment cycle,the ALT recovery rate,HBV-DNA negative conversion rate,and HBeAg negative conversion rate of treatment group 1were slightly higher than those of treatment group 2,but with no significant difference between the two groups,P〉0.05.The drug resistance rate of treatment group 1was higher than that of treatment group 2,P〈0.05.Conclusion：The nucleoside（acid）analogues such as entecavir and adefovir dipivoxil in the treatment of lamivudine-resistant chronic hepatitis B patients can get good effect,but long-term use of entecavir is easy to produce drug resistance.
出处
《数理医药学杂志》
2016年第12期1832-1833,共2页
Journal of Mathematical Medicine
关键词
拉米夫定耐药慢性乙肝
核苷(酸)类似物
疗效
lamivudine-resistant chronic hepatitis B
nucleoside（acid）analogues
efficacy
